J&J’s potential ‘game-changer’ drug — plus, what Microsoft’s mass buyouts mean

Share

Stocks broadly rebounded on Monday, supported by a return to artificial-intelligence-related shares after last week’s losses. Meta Platforms said it plans to raise up to $95 billion in equity, SpaceX announced a $40 billion debt raise to finance Nvidia GPU purchases, and Anthropic filed for an initial public offering. Johnson & Johnson revealed that 12 of 16 patients, or 75%, with advanced prostate cancer who received the oral drug JNJ-6143 achieved a complete or partial tumor response, results Leerink analysts described as potentially changing the outlook for the company’s oncology franchise. Microsoft is also offering voluntary buyouts to around 60,000 eligible employees as it optimizes its operating structure while investing in artificial-intelligence infrastructure; its free cash flow is expected to reach roughly $8 billion, compared with outflows of $9.9 billion at Amazon and $2.3 billion at Alphabet.

Source: Read the original article

Disclaimer: this content is for information purposes only and is not financial advice. Cryptocurrencies are highly volatile: you may lose all of your capital. Always do your own research. Legal notice
Telemac
Telemachttp://cryptoinfo.ch
Passionné de nouvelles technologies, j’explore l’univers de la blockchain et des cryptomonnaies pour partager l’actualité et les innovations du secteur.

Read More

Items